Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment

<div>Correlations between variations (delta) in total cholesterol (Tot-Chol), low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, and triglyceride (TG) plasmatic levels and variation (delta) of the DAS28 (a) and CDAI (b) after 24 weeks of tocilizumab treatment.</div>

Mediators of Inflammation

fig3

Figure 3

Figure 3: Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment 